Allergan Receives 2017 ENERGY STAR® Partner of the Year – Sustained Excellence Award from U.S. Environmental Protection Agency
Company Recognized with ENERGY STAR Award for Sixth Time
DUBLIN, April 10, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that it has been named a 2017 ENERGY STAR Partner of the Year – Sustained Excellence Award winner. The Company has been recognized for continued leadership in protecting the environment through superior energy efficiency achievements. Allergan will be recognized by the U.S. Environmental Protection Agency and the U.S. Department of Energy in Washington, D.C. on April 26, 2017.
Allergan has been an ENERGY STAR partner since 1996 and is being recognized by the EPA for the sixth time. The 2017 Partner of the Year – Sustained Excellence Awards are presented to organizations recognizing their contributions to reducing harmful carbon pollution through superior energy efficiency efforts. These awards recognize ongoing leadership in the ENERGY STAR program. Additionally, five buildings at the Allergan campus in Irvine, CA achieved ENERGY STAR certification for being in the top 25 percent of energy performance nationwide.
“Allergan has a long history and commitment to improving our energy performance and reducing our impact on the environment, and we are proud to once again be recognized by ENERGY STAR for our efforts,” said Wayne Swanton, Senior Vice President, Global Operations at Allergan. “Our partnership is part of our commitment to becoming more responsible stewards of energy use and the environment, including using greener sources of energy and reducing greenhouse gas emissions in our global operations.”
For a complete list of 2017 winners and more information about ENERGY STAR’s awards program, visit ww.energystar.gov/awardwinner…
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices, surgical and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com.
About ENERGY STAR
ENERGY STAR has 16,000 partners working to protect the environment through greater energy efficiency, including manufacturers, retailers, public schools, hospitals, real estate companies, and home builders. Since 1992, ENERGY STAR and its partners have saved American families and businesses $430 billion on their energy bills and 4.6 trillion kilowatt-hours of energy, while achieving broad emissions reductions—including 2.8 billion metric tons of greenhouse gas emissions.
ENERGY STAR® is the simple choice for energy efficiency. For 25 years, EPA’s ENERGY STAR program has been America’s resource for saving energy and protecting the environment. Join the millions already making a difference at energystar.gov.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Allergan plc